Assembly Biosciences Deal History & Licensing Activity
Assembly Biosciences is a biotech headquartered in US. Over the past three years, Assembly Biosciences has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 2 active clinical trials, primarily in Infectious Disease.
Deals (12mo)
2
Active Trials
2
Top Modality
Small Molecules
Focus Area
Infectious Disease
Assembly Biosciences Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Assembly Biosciences in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| GS-1179 and GS-5366 | Gilead Sciences | Small Molecules | Phase 1 | collaboration | Sep 8, 2026 |
| ABI-5366 + ABI-1179 (HSV) | Gilead Sciences | Small Molecules | Phase 1 | license | Dec 22, 2025 |
Assembly Biosciences Pipeline Focus
Therapeutic areas and modalities where Assembly Biosciences is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Assembly Biosciences Strategic Signals
Key indicators of Assembly Biosciences's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Assembly Biosciences Clinical Pipeline
Assembly Biosciences has 2 active clinical trials across 2 development phases.
1
Phase 1
1
Phase 2
See How Your Asset Matches Assembly Biosciences's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Assembly Biosciences Licensing & Deal Activity
Assembly Biosciences is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Assembly Biosciences ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Assembly Biosciences include Infectious Disease (4 deals and trials), Infectious (1 deal and trial), and Gastroenterology (1 deal and trial). In terms of modality, Assembly Biosciences has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Assembly Biosciences and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Assembly Biosciences's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.